Posted By:Paul Stoffels, Worldwide Chairman, Pharmaceuticals at Johnson & Johnson CNBC Guest Blog
It’s rare for the world's leading pharmaceutical companies and other partners to work together to tackle an urgent global health issue. It’s time for this to change and our new coordinated effort – unlike previous siloed, disease-by-disease approaches – is the first step. Read More
Amgen and Celgene, looking to boost oncology offerings, announced separate deals for small biotech companies Thursday, the latest in what analysts expect to be a major wave of biotech mergers. Read More
As the JPMorgan Health Care conference kicks off this week, one question remains for investors in the biotech space. What’s the next takeover target as large drug makers look to build out their pipeline? Read More
The "Patient Protection and Affordable Care Act" has been a lightning rod since its inception. Both sides of the aisle have used a different set of numbers to support stances both for and against the law. Read More
We have worried A LOT in the past few years—jobs, money, the stock market—you name it. But guess what? It has yet to be scientifically proven that worrying can fix a problem. So here are 8 tips to help you stop worrying — or, at the very least, to do it properly! Read More
The health care sector had a good year in 2011 — the group was one of only two sectors out of 10 major categories within the S&P 1200 to deliver positive returns on both a price and total return basis. But 2012 brings a new set of challenges, reports TheStreet.com. Read More